Home//BPC-157

What is BPC-157?

BPC-157 is a synthetic peptide based on a sequence found in a protein in human gastric juice. In wellness and athletic communities it is promoted for repairing tendons, ligaments, muscle and gut tissue, and it features in popular peptide “stacks.” It has never been approved as a medicine in the United States.

What the evidence shows

EVIDENCE GRADE · PRECLINICAL · MINIMAL HUMAN DATA

Human evidence is minimal. A 2025 systematic review of orthopedic and sports-medicine use (Vasireddi et al., PMID 40756949) identified 36 studies — 35 preclinical and only one clinical. The main human dataset is a small, uncontrolled retrospective review of about 16 knee-pain patients. A Phase II placebo-controlled hamstring-strain trial (NCT07437547) is recruiting in 2026 with no results yet; an earlier oral Phase I (NCT02637284) studied healthy volunteers. The FDA placed BPC-157 in Category 2 in 2023, citing concerns including immunogenicity, peptide-related impurities, and insufficient human data.

Is it legal?

BPC-157 is not FDA-approved. In April 2026 it was removed from FDA Category 2 but not moved to the approved Category 1 list, so legal compounding is not authorized; the PCAC reviews it on July 23, 2026.

FDA approvalNot approved
Compounding statusRemoved from Category 2 (Apr 2026, nominations withdrawn) · not on Category 1 — compounding not authorized
Under FDA reviewPCAC · July 23, 2026
Use under reviewUlcerative colitis
Earliest pharmacy accessLate 2026–Q1 2027 (if cleared)
Will BPC-157 become legal in 2026?+
Not automatically. The committee meets July 23, 2026; a favorable vote is a recommendation only — the FDA must then issue a final rule, which typically takes months. Realistic legal compounded access is late 2026 to Q1 2027, and only if both steps go through.
Is “research-grade” BPC-157 the same as a medicine?+
No. Material sold “for research use only” is not made or tested to pharmaceutical standards, is not authorized for human use, and carries no guarantee of identity, purity or sterility. This site does not link to or evaluate these sellers.

Primary sources: 2025 review: PMID 40756949 · trials: ClinicalTrials.gov NCT07437547, NCT02637284 · FDA 503A interim list · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.

Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. BPC-157 is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.